Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
52.95
+0.14 (0.27%)
At close: Jul 24, 2026, 4:00 PM EDT
53.00
+0.05 (0.09%)
After-hours: Jul 24, 2026, 7:56 PM EDT

Enliven Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-115.79-119.66-104.55-83.53-38.79-51.44
Net Income
-98.78-103.69-89.02-71.58-37.66-51.38
Earnings Per Share
-1.67-1.83-1.89-2.01-12.05-9.48
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
452.4462.62313.44253.1575.5490.28
Total Debt
000000.65
Net Cash (Debt)
452.4462.62313.44253.1575.5489.63
Net Cash Growth
56.24%47.59%23.82%235.14%-15.72%1.59%
Net Cash Per Share
7.568.166.667.1224.1825.75

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-65.47-70.3-73.19-61.27-32.08-46.77
Capital Expenditures
-0.14-0.16-0.04-0.15-0.61-0.01
Free Cash Flow
-65.6-70.46-73.24-61.42-32.69-46.78
Free Cash Flow Growth
------